Thomas Powles, MD, MBBS, MRCP

Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Clinical pearls of advice regarding the optimal management of metastatic urothelial carcinoma in today’s treatment landscape.

Expert perspectives on novel treatment approaches being investigated in the second-line setting of metastatic urothelial carcinoma and beyond.

Practical advice on maintenance therapy in metastatic urothelial carcinoma, covering patient education, duration of therapy, and clinical guidelines.

A review of the JAVELIN Bladder 100 trial, which evaluated avelumab maintenance therapy following frontline chemotherapy in metastatic urothelial carcinoma.

The overall impact that maintenance therapy has had on patient outcomes in advanced or metastatic urothelial carcinoma.

Thomas Powles, MD, MBBS, MRCP, discusses the utility of maintenance avelumab in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the design and findings of the phase Ib BISCAY trial in platinum-refractory urothelial cancer.

Thomas Powles, MBBS, MRCP, MD, discusses the importance of accurately assessing the toxicity profiles of immunotherapies for renal cell carcinoma.

Thomas Powles, MD, MBBS, MRCP, professor, Genitourinary Oncology, lead for Solid Tumour Research, and director, Barts Cancer Institute, discusses the use of PD-L1 as a biomarker in renal cell carcinoma (RCC).